Interferon epsilon promotes HIV restriction at multiple steps of viral replication

Immunology and Cell Biology

Volumn 95, Issue 5, 2017, Pages 478-483

  Garcia Minambres, Albert ^a,b   Eid, Sahar G ^a,b   Mangan, Niamh E ^c,d   Pade, Corinna ^a,b   Lim, San S ^c,d   Matthews, Antony Y ^c,d   De Weerd, Nicole A ^c,d   Hertzog, Paul J ^c,d   Mak, Johnson ^a,b  

^a DEAKIN UNIVERSITY   (Australia)

^b CSIRO   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BETA INTERFERON; BST2 PROTEIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENTARY DNA; HERC5 PROTEIN; IFITM3 PROTEIN; INTERFERON; PHYTOHEMAGGLUTININ; PROTEIN; RECOMBINANT INTERFERON; RECOMBINANT INTERFERON EPSILON; THROMBOSPONDIN; TRANSCRIPTION FACTOR EMX2; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRAL PROTEIN; INTERFERON-EPSILON, HUMAN;

ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; DRUG POTENCY; FEMALE; HELA CELL LINE; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON INDUCTION; PROGENY; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENE; VIRUS RELEASE; VIRUS REPLICATION; DRUG EFFECTS; EPITHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

EPITHELIAL CELLS; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; INTERFERONS; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES; VIRION; VIRUS REPLICATION;

EID: 85008354094     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2016.123     Document Type: Article

References (41)

1. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics 2004; 84: 331-345.
2. Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA et al. Interferonepsilon protects the female reproductive tract from viral and bacterial infection. Science 2013; 339: 1088-1092.
3. Demers A, Kang G, Ma F, Lu W, Yuan Z, Li Y et al. The mucosal expression pattern of interferon-epsilon in rhesus macaques. J Leukoc Biol 2014; 96: 1101-1107.
4. Curlin ME, Leelawiwat W, Dunne EF, Chonwattana W, Mock PA, Mueanpai F et al. Cyclic changes in HIV shedding from the female genital tract during the menstrual cycle. J Infect Dis 2013; 207: 1616-1620.
5. Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57: 261-264.
6. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485.
7. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol 2015; 13: 403-413.
8. Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol 2015; 16: 546-553.
9. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013; 502: 559-562.
10. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 2013; 14: 398-410.
11. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013; 502: 563-566.
12. Woods MW, Tong JG, Tom SK, Szabo PA, Cavanagh PC, Dikeakos JD et al. Interferoninduced HERC5 is evolving under positive selection and inhibits HIV-1 particle production by a novel mechanism targeting Rev/RRE-dependent RNA nuclear export. Retrovirology 2014; 11: 27.
13. Woods MW, Kelly JN, Hattlmann CJ, Tong JG, Xu LS, Coleman MD et al. Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of Gag. Retrovirology 2011; 8: 95.
14. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430.
15. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3: 245-252.
16. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
17. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. J Virol 2011; 85: 2126-2137.
18. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology 2014; 11: 103.
19. Abdool Karim Q, Sibeko S, Baxter C. Preventing HIV infection in women: a global health imperative. Clin Infect Dis 2010; 50: S122-S129.
20. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71: 5871-5877.
21. Peng FW, Duan ZJ, Zheng LS, Xie ZP, Gao HC, Zhang H et al. Purification of recombinant human interferon-epsilon and oligonucleotide microarray analysis of interferon-epsilon-regulated genes. Protein Expr Purif 2007; 53: 356-362.
22. Byrne EH, Anahtar MN, Cohen KE, Moodley A, Padavattan N, Ismail N et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis 2016; 16: 441-448.
23. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15: 181-189.
24. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data metaanalysis. PLoS Med 2015; 12: e1001778.
25. Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM et al. Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV 2015; 2: e279-e287.
26. Saba E, Origoni M, Taccagni G, Ferrari D, Doglioni C, Poli G et al. Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunol 2013; 6: 1081-1090.
27. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2: 1084-1089.
28. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22: 1909-1917.
29. D'Ortenzio E, Matheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G et al. Evidence of sexual transmission of Zika virus. N Engl J Med 2016; 374: 2195-2198.
30. Savidis G, Perreira JM, Portmann JM, Meraner P, Guo Z, Green S et al. The IFITMs inhibit Zika virus replication. Cell Rep 2016; 15: 2323-2330.
31. Izquierdo-Useros N, Lorizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson E et al. Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol 2012; 10: e1001448.
32. Eid SG, Mangan NE, Hertzog PJ, Mak J. Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses. Clin Transl Immunology 2015; 4: e43.
33. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis 2015; 61: 1601-1603.
34. Coelho AV, De Moura RR, Da Silva RC, Kamada AJ, Guimaraes RL, Brandao LA et al. Meta-analysis and time series modeling allow a systematic review of primary HIV-1 drugresistant prevalence in Latin America and Caribbean. Curr HIV Res 2015; 13: 125-142.
35. Abdulhaqq SA, Zorrilla C, Kang G, Yin X, Tamayo V, Seaton KE et al. HIV-1-negative female sex workers sustain high cervical IFN?, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunol 2016; 9: 1027-1038.
36. Veazey RS, Pilch-Cooper HA, Hope TJ, ALter G, Carias AM, Sips M et al. Prevention of SHIV transmission by topical IFN-treatment. Mucosal Immunol 2016; 9: 1528-1536.
37. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014; 511: 601-605.
38. Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol 2001; Chapter 7: Unit 7. 1.
39. Hwang SY, Hertzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci USA 1995; 92: 11284-11288.
40. Gomez AM, Ouellet M, Tremblay MJ. HIV-1-triggered release of type I IFN by plasmacytoid dendritic cells induces BAFF production in monocytes. J Immunol 2015; 194: 2300-2308.
41. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005; Chapter 12: Unit 12. 11.